Actively Recruiting
Phase II Study Comparing RO7965032 Doses to Placebo in Geographic Atrophy from Age-Related Macular Degeneration
Led by Genentech, Inc. · Updated on 2026-10-26
321
Participants Needed
5
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating RO7965032 for safety and effectiveness in people with geographic atrophy GA caused by age-related macular degeneration AMD. This condition currently has significant unmet medical needs. The study is a Phase II, randomized, double-masked, placebo-controlled trial designed to assess how RO7965032 may impact GA progression and related symptoms. Participants will be randomly assigned to receive one of two dose levels of RO7965032 or a placebo. The drug and placebo are given according to a schedule specified in the study protocol. The trial includes monitoring treatment effects and safety over a period of approximately 48 to 72 weeks, with different assessments throughout this time. During the study, participants will undergo eye examinations, imaging, and vision tests such as the Best Corrected Visual Acuity BCVA using the ETDRS chart under normal and low light. Blood samples will be collected to measure drug levels, protein targets, and biomarkers. Researchers will track adverse events related to eyes or other parts of the body. The main measurement is change in GA lesion size over about 48 weeks, with continued observation up to 72 weeks. The total participation time lasts until study completion, including safety and efficacy evaluations.
CONDITIONS
Brief Title
A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Research Team
R
Reference Study ID Number: XR46785 https://forpatients.roche.com/No attachments to email below.
F
Fastest Response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here